Concit Pharma in NY
Concit Pharma paricipated in the Danish Life Sciences Investor Forum in New York on 30.09.2013 to 02.10.2013.
Contera Pharma: new name and organisation
Concit Pharma has changed its corporate name to Contera Pharma, effective from 19.11.2013. As of 19.11.2013 Don deBethizy is appointed chairman of the board. Don is the former CEO of Targacept, Inc a public biotech company discovering and developing novel small molecules targeting serious CNS disorders. Don will help the company to explore financing opportunities […]
Bukwang Pharmaceuticals acquires Contera Pharma
Contera Pharma announces acquisition by Korean Bukwang Pharmaceutical JM-010 to enter global development for L-DOPA induced dyskinesia Contera Pharma (Copenhagen, Denmark) is pleased to announce that Bukwang Pharmaceutical (Seoul, Korea) has acquired 100% of Contera Pharma from its current shareholders. The shareholders received an undisclosed upfront payment and are entitled to future contingent and royalty […]
Solural Pharma and Contera Pharma initiate Eurostar sponsored project in Parkinson’s disease
Solural Pharma and Contera Pharma have in collaboration with Ernst Moritz Arndt University Greifswald, Germany and Erweka GmbH, Germany been awarded a Eurostar grant to support a project to develop new treatments of morning akinesia associated with Parkinson’s disease (PD). Parkinson’s disease, which affects 1 in 100 people over the age of 60, is primarily […]
Press release, JM-010CS01, Phase IIa/cPoC study
Bukwang Pharma and its fully owned subsidiary Contera Pharma are pleased to announce that the investigational medical product, JM-010 has been dosed to the first patients with Parkinson’s disease suffering from moderate to severe levodopa-induced dyskinesia. The Phase IIa/Proof-of-Concept study is a randomized, double-blind, placebo-controlled, 2-way crossover study, which will assess the efficacy, safety/tolerability and […]
US patent covering JM-010 for treatment of movement disorders has been granted
Bukwang Pharm and its fully owned subsidiary Contera Pharma are pleased to announce that the United State patent covering the investigational medical product, JM-010 and analogues thereof has been granted. Dr. Hee-Won Yoo, President and co-CEO of Bukwang Pharm stated: “The US patent is a significant milestone for Bukwang Pharm and supports the further development […]
